Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal

Proietti, Marco ORCID: 0000-0003-1452-2478 and Boriani, Giuseppe (2018) Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 14. pp. 1483-1488.

Access the full-text of this item by clicking on the Open Access link.

Text Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal.pdf - Published version Download (963kB) | Preview

Abstract

Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. Idarucizumab was approved in 2015 by the US Food and Drugs Administration and European Medicines Agency for reversal of anticoagulation activity in dabigatrantreated patients. This review briefly summarizes the experimental evidence about effectiveness and safety of idarucizumab. Furthermore, we review the current recommendations and experts' point of view about the use of antidotes/reversal agents in patients reporting a major bleeding event.

Item Type:	Article
Uncontrolled Keywords:	anticoagulant drugs, non-vitamin K antagonist oral anticoagulants, reversal agents, idarucizumab, major bleeding
Depositing User:	Symplectic Admin
Date Deposited:	17 May 2019 10:33
Last Modified:	19 Jan 2023 00:45
DOI:	10.2147/TCRM.S140377
Open Access URL:	http://doi.org/10.2147/TCRM.S140377
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3041760